HPLC法测定鹿仙口服液中淫羊藿苷的含量

建立鹿仙口服液中淫羊藿苷的含量测定方法。采用高效液相色谱法测定鹿仙口服液中淫羊藿苷的含量 ,使用 C18柱 ,乙腈 -水 (2 5∶ 75 )为流动相 ,检测波长为 2 70 nm。结果淫羊藿苷浓度在 9～ 4 7μg/ ml范围内线性关系良好 ,本法重现性好 ,精密度高 ,平均回收率为 99.4 % ,RSD =2 .1% ,可用于鹿仙口服液质量控制     

薄层扫描法测定神雄精口服液中淫羊藿苷的含量

目的　为控制药物的内在质量 ,对神雄精口服液中淫羊藿苷进行定量分析。方法　采用薄层扫描法。结果　样品神雄精口服液中淫羊藿苷的含量为 0 .2 1 8mg/ml,加样回收率平均值为 98.1 3 % ,同一块板精密度测定结果RSD =1 .0 9% ,异板精密度测定结果RSD =2 .2 8%。结论　测定方法简单 ,准确可靠。     

延年乐口服液含量测定的研究

目的建立高效液相色谱法测定延年乐口服液中淫羊藿苷的含量,以增加对制剂的质量控制。方法采用迪马公司(DIKMA)十八烷基硅烷键合硅胶,4.6×150mm5μm色谱柱,以甲醇-水(65∶35)为流动相,检测波长为270nm。结果淫羊藿苷浓度在18.968~113.808μg.mL-1范围内线性关系良好,r=1.000,平均回收率为97.45%,RSD为1.70%。结论本法测定淫羊藿苷简便、准确、重现性好,可用于延年乐口服液中淫羊藿苷的含量测定。     

不同产地和品种淫羊藿中淫羊藿苷的HPLC分析

目的 :对中药淫羊藿中淫羊藿苷的含量分析进行方法学研究 ,并测定淫羊藿的不同产地、不同品种、不同药用部位的淫羊藿苷的含量。方法 :采用RP HPLC技术对 7个品种 2 3个样品进行测定。以PERKIN EIMER SH/5C18柱为分析柱 ,流动相为乙腈 水 36%乙酸 ( 2 5∶73.5∶1 .5)流速 1 .0ml/min。UV检测波长 2 70nm。结果 :本方法测定淫羊藿苷含量在 0 .0 2 1 2～ 0 .1 2 7μg ,0 .53～ 1 .696μg范围内呈良好的线性关系。不同产地、不同品种、不同药用部位的淫羊藿其淫羊藿苷的含量为 0 .0 0 30 7%～ 1 .55%。同一植株不同部位中淫羊藿苷的含量分布叶 >叶茎 >茎 >根。结论 :淫羊藿由于产地不同、品种不同其淫羊藿苷的含量相差悬殊。本测定方法为筛选优良品种和扩大药源提供了简便易行的方法     

RP-HPLC法测定补肾强身片中淫羊藿苷的含量

采用高效液相色谱法测定补肾强身片中淫羊藿苷的含量 ,以C18化学键合硅胶柱分离淫藿苷 ,以乙腈 -水 -醋酸(2 5∶75∶1)为流动相 ,UV检测波长 2 70nm进行测定。淫羊藿苷峰与其它组分峰的分离度为 6 0 ,理论塔板数以淫羊藿苷计算为 12 5 0 0 ;方法的平均回收率为 97 6 % ,RSD为 0 5 % (n =5 ) ,淫羊藿苷进样量与吸收面积分值呈良好的线性关系。线性范围 0 2 5～ 2 5 μg。本法测定补肾强身片中淫羊藿苷的含量 ,结果准确 ,重复性好     

延年乐口服液中淫羊藿苷的鉴别和含量测定

目的:建立延年乐口服液中淫羊藿的鉴别和含量测定的标准,以增加对制剂主药的质量控制.方法:以淫羊藿苷作对照品,采用薄层色谱法做鉴别;高效液相色谱法做含量测定.结果:检出供试品淫羊藿苷清晰的斑点;含量测定淫羊藿苷浓度18.968～113.808μg/ml范围内线性关系良好(r=1.000),平均回收率为97.45%,RSD为1.70%.结论:本法测定淫羊藿苷简便、专属性强、准确、重现性好,可用于延年乐口服液淫羊藿苷鉴别和含量测定.     

藿蓉补肾颗粒的质量控制方法

目的　建立藿蓉补肾颗粒的质量控制方法。方法　采用薄层色谱法对该药中淫羊藿、肉苁蓉进行薄层鉴别 ;采用高效液色相谱法对该药的淫羊藿苷进行含量测定。结果　在TLC色谱图中可检出淫羊藿、肉苁蓉 ;淫羊藿苷在 0 0 10 4～ 0 0 5 2 0mg·ml-1浓度范围内呈良好的线性关系 (r=0 9997) ,平均回收率为 96 1% ,RSD =1 5 %。结论　所用方法简便、准确。     

HPLC测定更年灵胶囊中淫羊藿苷的含量

目的 　建立更年灵胶囊中淫羊藿苷含量的 HPL C测定方法。方法 　色谱柱为 Nova-pak( 15 0 mm× 4.6mm ,5μm) C1 8柱 ,乙腈 -水 ( 2 6∶ 74)为流动相 ,检测波长 ;2 70 nm。 结果 　淫羊藿苷在 2 0 .2 6～ 162 .0 μg·L- 1 ,范围内呈良好的线性关系 ,r=0 .9998,平均回收率为 10 0 .1% ,RSD=1.1% ( n=5 )。 结论 　方法结果准确 ,重现性好 ,可用于测定更年灵胶囊中淫羊藿苷的含量。     

高效液相色谱法测定强阳灵口服液中淫羊藿苷的含量

目的 建立高效液相色谱法测定强阳灵口服液中淫羊藿苷含量的方法。方法采用HPLC法，在波长284mm以乙腈-水(23：77)为流动相。测定淫羊藿苷的含量。结果淫羊藿苷在0．241～1．203μg范围内呈良好线性关系(r=0．9995)平均回收率为99.0％(RSD=1．0％，n=5)。测定5批样品的RSD为0．5～0．9％。结论所建立的方法可准确进行定量检测，可用于该制剂的质量控制。     

HPLC同时测定21种淫羊藿中朝藿定C和淫羊藿苷的含量

目的:建立同时测定淫羊藿药材中朝藿定C和淫羊藿苷含量的高效液相色谱方法。方法:采用Elite SinoChrom ODS-AP(250 mm×4.6 mm,5μm)色谱柱,流动相为乙腈(A)-水(B),梯度洗脱(0~8 min,27%A;8~30 min,27%A→29%A),流速1 mL.min-1,检测波长270 nm。结果:朝藿定C进样量在0.130~3.89μg,淫羊藿苷在0.0294~1.47μg范围内呈良好线性关系(r=0.9999);朝藿定C和淫羊藿苷平均回收率(n=9)分别为103.9%,100.0%;淫羊藿药材中朝藿定C和淫羊藿苷的含量分别为0.02%~7.80%,0.01%~1.74%。结论:该方法简便、快速、准确,重复性好,可作为淫羊藿药材中朝霍定C和淫羊藿苷的含量测定方法。     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.     

Gender-related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders

This study explored gender-related symptoms and correlates of alcohol dependence in a crosssectional study of 150 men and 150 women with a lifetime diagnosis of alcohol use disorders (AUD). Participants were recruited in equal numbers from treatment settings, correctional centres and the general community. Standardized measures were used to determine participants' use of substances, history of psychiatric disorders and psychosocial stress, their sensation seeking and family history of substance use and mental health disorders. Multivariate analyses were used to detect patterns of variables associated with gender and the lifetime severity of AUD. Men had a longer history of severe AUD than women. Women had similar levels of alcohol dependence and medical and psychological sequelae as men, despite 6 fewer years of AUD. More women than men had a history of severe psychosocial stress, severe dependence on other substances and antecedent mental health problems, especially mood and anxiety disorders. There were differences in family history of alcohol-related problems approximating same-gender aggregation. The severity of a lifetime AUD was predicted by its earlier age at onset and the occurrence of other disorders, especially anxiety, among both men and women. The limitations in the generalizability of these findings due to sample idiosyncrasies are discussed.     

Biochemical and molecular characterisation of cubozoan protein toxins

Class Cubozoa includes several species of box jellyfish that are harmful to humans. The venoms of box jellyfish are stored and discharged by nematocysts and contain a variety of bioactive proteins that are cytolytic, cytotoxic, inflammatory or lethal. Although cubozoan venoms generally share similar biological activities, the diverse range and severity of effects caused by different species indicate that their venoms vary in protein composition, activity and potency. To date, few individual venom proteins have been thoroughly characterised, however, accumulating evidence suggests that cubozoan jellyfish produce at least one group of homologous bioactive proteins that are labile, basic, haemolytic and similar in molecular mass (42-46 kDa). The novel box jellyfish toxins are also potentially lethal and the cause of cutaneous pain, inflammation and necrosis, similar to that observed in envenomed humans. Secondary structure analysis and remote protein homology predictions suggest that the box jellyfish toxins may act as α-pore-forming toxins. However, more research is required to elucidate their structures and investigate their mechanism(s) of action. The biological, biochemical and molecular characteristics of cubozoan venoms and their bioactive protein components are reviewed, with particular focus on cubozoan cytolysins and the newly emerging family of box jellyfish toxins.     

Dose tolerability of chronically inhaled voriconazole solution in rodents

Invasive pulmonary aspergillosis (IPA) is a fungal disease of the lung associated with high mortality rates in immunosuppressed patients despite treatment. Targeted drug delivery of aqueous voriconazole solutions has been shown in previous studies to produce high tissue and plasma drug concentrations as well as improved survival in a murine model of IPA. In the present study, rats were exposed to 20 min nebulizations of normal saline (control group) or aerosolized aqueous solutions of voriconazole at 15.625 mg (low dose group) or 31.25 mg (high dose group). Peak voriconazole concentrations in rat lung tissue and plasma after 3 days of twice daily dosing in the high dose group were 0.85 ± 0.63 μg/g wet lung weight and 0.58 ± 0.30 μg/mL, with low dose group lung and plasma concentrations of 0.38 ± 0.01 μg/g wet lung weight and 0.09 ± 0.06 μg/mL, respectively. Trough plasma concentrations were low but demonstrated some drug accumulation over 21 days of inhaled voriconazole administered twice daily. Following multiple inhaled doses, statistically significant but clinically irrelevant abnormalities in laboratory values were observed. Histopathology also revealed an increase in the number of alveolar macrophages but without inflammation or ulceration of the airway, interstitial changes, or edema. Inhaled voriconazole was well tolerated in a rat model of drug inhalation.